

Immunotherapy Drugs Market Size To Reach US\$ 327.8 Billion by 2028 | CAGR Of 8.9%

The expanding geriatric population and the increasing prevalence of cancer, tumor, and target diseases are driving the immunotherapy drugs market

SHERIDAN, WYOMING, UNITED STATES, April 11, 2023 /EINPresswire.com/ --

The latest research study

"Immunotherapy Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" by IMARC Group, finds that the global immunotherapy drugs market size reached US\$ 195.4 Billion in 2022.

Looking forward, IMARC Group expects the market to reach [US\\$ 327.8 Billion by 2028](#), exhibiting a growth rate (CAGR) of 8.9% during 2023-2028.



Immunotherapy Drugs Market

Immunotherapy drugs represent specialized medications utilized for treating lymphoma, sarcoma, melanoma, and lung, kidney, bladder, and breast cancer. Some of the common types include monoclonal antibodies, vaccines, interleukins, interferons alpha and beta, etc. Immunotherapy drugs target specific cells of the immune system, stimulate the natural defenses of the body, boost energy levels, and fight against allergies and infections caused by viruses and bacteria. They even help to prevent the growth of cancer cells by triggering immunological responses that assist in generating antibodies and prove extremely effective in decreasing the complications of tumors and other chronic disorders. Consequently, immunotherapy drugs find widespread applications in hospitals and clinics across the globe.

Request a free sample brochure: <https://www.imarcgroup.com/immunotherapy-drugs-market/requestsampl>

Immunotherapy Drugs Market Trends and Drivers:

The expanding geriatric population and the increasing prevalence of cancer, tumor, and target diseases are among the key factors driving the immunotherapy drugs market. Additionally, the

rising usage of monoclonal antibodies and biosimilar drugs to treat genetic and lifestyle ailments is acting as another significant growth-inducing factor. Apart from this, the elevating focus of leading market players on strategic collaborations for developing new products to expand their product portfolio and gain a competitive edge is also positively influencing the market growth. Moreover, the escalating awareness among the masses about the advantages of early detection and treatment of cancer and the launch of favorable reimbursement policies are further stimulating the global market. Besides this, the growing number of research laboratories across countries and the inflating investments in healthcare infrastructure development are expected to bolster the immunotherapy drugs market in the coming years.

Inquire Before Buying: <https://www.imarcgroup.com/request?type=report&id=6639&flag=F>

Immunotherapy Drugs Market Report Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

- AstraZeneca plc
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- GSK plc, Merck & Co. Inc.
- Pfizer Inc. and Sanofi S.A.

The report has been segmented the market into following categories:

Breakup by Type:

- Monoclonal Antibodies
- Vaccines
- Interferons Alpha and Beta
- Interleukins

Breakup by Therapy Area:

- Cancer
- Autoimmune and Inflammatory Diseases
- Infectious Diseases
- Others

Breakup by End User:

- Hospitals
- Clinics
- Others

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure:

<https://www.imarcgroup.com/immunotherapy-drugs-market>

Breakup by Region:

- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa

Key highlights of the report:

- Market Performance (2017-2022)
- Market Outlook (2023- 2028)
- Porter's Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Also Read:

- <https://www.openpr.com/news/2997935/toothpaste-market-share-2023-2028-top-brands>
- <https://www.openpr.com/news/2997896/commercial-refrigeration-market-to-expand-at-a-growth-rate>
- <https://www.openpr.com/news/2998712/sanitary-ware-market-research-report-2023-2028-industry-size>
- <https://www.openpr.com/news/2985388/feed-premix-market-worth-us-26-6-billion-by-2028-exclusive>
- <https://www.openpr.com/news/2985526/advanced-packaging-market-growth-rate-cagr-11-2-revenue>

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Elena Anderson
IMARC Services Private Limited
+1 6317911145
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/627241393>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.